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Abstract
Purpose: To elucidate the role of biological and clinical impact of aberrant promoter hypermethylation (PH) in ovarian
cancer (OC).
Experimental Design: PH of PGP9.5, HIC1, AIM1, APC, PAK3, MGMT, KIF1A, CCNA1, ESR1, SSBP2, GSTP1, FKBP4 and VGF were
assessed by quantitative methylation specific PCR (QMSP) in a training set. We selected two genes (VGF and PGP9.5) for
further QMSP analysis in a larger independent validation (IV) set with available clinical data. Biologic relevance of VGF gene
was also evaluated.
Results: PH frequency for PGP9.5 and VGF were 85% (316/372) and 43% (158/366) respectively in the IV set of samples while
no PH was observed in controls. In 372 OC cases with available follow up, PGP9.5 and VGF PH were correlated with better
patient survival [Hazard Ratios (HR) for overall survival (OS) were 0.59 (95% Confidence Intervals (CI) = 0.42–0.84, p = 0.004),
and 0.73 (95%CI = 0.55–0.97, p = 0.028) respectively, and for disease specific survival (DSS) were 0.57 (95%CI 0.39–0.82,
p = 0.003) and 0.72 (95%CI 0.54–0.96, p = 0.027). In multivariate analysis, VGF PH remained an independent prognostic factor
for OS (HR 0.61, 95%CI 0.43–0.86, p,0.005) and DSS (HR 0.58, 95%CI 0.41–0.83, p,0.003). Furthermore, PGP9.5 PH was
significantly correlated with lower grade, early stage tumors, and with absence of residual disease. Forced expression of VGF
in OC cell lines inhibited cell growth.
Conclusions: Our results indicate that VGF and PGP9.5 PH are potential biomarkers for ovarian carcinoma. Confirmatory
cohorts with longitudinal follow-up are required in future studies to define the clinical impact of VGF and PGP9.5 PH before
clinical application.
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Introduction
Ovarian cancer (OC) is the second most common gynecological
cancer and the leading cause of death among gynecological
cancers worldwide [1]. 22,240 new cases were estimated for 2013
in the United States, leading to 14,030 deaths from this cancer
type [2]. The median age of patients with OC is 60 years, and the
average lifetime risk for developing OC in women is about 1 in 70
[3]. Seventy percent of patients with OC have advanced disease
(stage III or IV) at the time of diagnosis, with a 5-year survival rate
of 15 to 20% despite aggressive treatment [4], in comparison to
the early stage patients with a survival rate above 90% [3]. OC has
been generally treated with platinum-based chemotherapy and
often recurs due to acquired platinum resistance. The initial
clinical response to platinum-based drugs is a major determinant
of outcome for patients with OC. Patients with tumors demon-
strating in vitro extreme drug resistance to platinum were found to
be at a significantly increased risk for progression and death when
treated with standard platinum-based regimens [5]. It is therefore
of major significance to identify useful predictive markers
indicating platinum sensitivity. These may allow better treatment
selection for the 1st line of treatment, possibly allowing better
outcome for the platinum resistant patients. Determination of
appropriate markers to anticipate response to standard chemo-
therapeutic or newer biologic agents will allow for improved
control and cure rates for OC, as well as selection of adjuvant
therapy or identification of patients appropriate for specific clinical
trials. Furthermore, the ability to predict OC outcomes after
surgical resection is critical for clinicians, as it would impact the
use of adjuvant chemotherapy and radiation therapies. An
independent prognostic indicator of OC survival would therefore
be invaluable to physicians and patients in selecting treatment
options.
It is known that genetic (changes in DNA sequence such as
deletions, amplifications and mutations) and epigenetic changes
(defined as heritable changes in gene expression that occur without
changes to the DNA sequence) contribute to the development and
progression of tumor cells [6]. The most common epigenetic
events include DNA methylation and histone acetylation [7],
being DNA methylation possibly the most widely studied aspect of
epigenetics with regard to carcinogenesis, and the key focus of
pharmacologic interventions in clinical trials. It refers to the
addition of a methyl group to the 5-carbon position of the cytosine
ring to form 5-methylcytosine (5mC), but only on cytosines that
precede a guanosine in the DNA sequence, known as CpG
dinucleotide [8]. There are CpG-rich regions known as CpG
islands which usually span the 59end region (promoter, untrans-
lated region and exon 1) of many genes with tumor suppressor
activity and are usually unmethylated in normal cells [9]. The
human genome in this normal cells is not methylated uniformly,
containing unmethylated segments interspersed with methylated
regions [10], whereas cancer cells methylation patterns are altered,
undergoing global DNA hypomethylation [11], as well as
hypermethylation of certain CpG islands [8]. Aberrant CpG
island hypermethylation (in particular in tumor suppressor genes’
promoter) as well as histone modification lead to transcriptional
inactivation and gene silencing, being a common phenomenon in
human cancer cells and likely one of the earliest events in
carcinogenesis [7]. In particular, promoter hypermethylation (PH)
is a frequent mechanism of inactivation of tumor suppressor genes
(TSGs) [7,8] and PH of certain cancer related genes were found to
be associated with therapeutic response and outcome of the disease
[12,13].
In the present study, we analyzed PH of 13 genes (PGP9.5,
HIC1, AIM1, APC, PAK3, MGMT, KIF1A, CCNA1, ESR1, SSBP2,
GSTP1, VGF, FKBP4) by quantitative fluorogenic real-time
methylation specific PCR (QMSP) in a training set and finally
tested two genes (VGF and PGP9.5) in an independent validation
set to evaluate whether there is any association of PH of these two
genes with any clinical factors including overall outcome of the
patient. Moreover, we studied the functional role of VGF as an
anti-tumorigenic molecule in OC derived cell lines.
Materials and Methods
Study cohort
Training Set. In order to compose the first set of samples we
obtained samples of ovarian tumor tissue from our tissue archive,
collected from 33 patients with epithelial OC who underwent
therapeutic surgery at The Johns Hopkins University School of
Medicine. We also obtained samples from 24 patients with OC
who underwent surgery at University Campus Bio-Medico, Rome
Italy. To be included in the cohort, an eligible patient had to have
a confirmed diagnosis of OC and a sufficient amount of archived
tumor material for DNA extraction. The samples were preserved
in paraffin, and a set of slides (10 microns of thickness) were taken
from each block. The demographic and clinical information was
obtained from the computerized tumor registry at The Johns
Hopkins Healthcare System or from the registry at Department of
Obstetrics and Gynecology, University Campus Bio-Medico of
Rome, Italy. The tumors were classified according to the FIGO
staging system [14]. From the Johns Hopkins patients (33), 16
patients presented with early stage disease (15 stage I and 1 stage
II) and 17 with advanced disease (14 stage III and 3 stage IV). All
the samples were epithelial ovarian carcinomas with a serous-
papillary histology. From the 24 patients from Italy, 10 had early
stage disease (6 with stage I, and 4 with stage II), 13 had advanced
disease (12 with stage III, and 1 with stage IV) and 1 had unknown
stage. Eighteen patients presented with epithelial ovarian carci-
nomas (serous, endometrioid, mucinous, squamous, undifferenti-
ated), one with germ cell tumor, four presented with secondary
(metastatic) tumors, and 1 patient had unknown histology. The
normal ovarian epithelium tissue was obtained from 13 patients
who underwent prophylactic surgery for any benign condition in
Hospital San Jose Tec de Monterrey in Mexico. A detailed
summary of the training set of patients is available in Table 1(A).
Independent Validation (IV) Set. We analyzed an inde-
pendent validation set for the most promising genes. This
independent set consisted of 372 ovarian tumors, 17 borderline
tumors and 18 ovarian cystadenomas (all preserved as fresh frozen
samples). These patients underwent surgery at the University
Medical Center Groningen, Groningen (UMCG), The Nether-
lands. The demographic and clinical information was obtained
from the registry at the Department of Gynecologic Oncology,
UMCG, The Netherlands. A detailed summary of the demo-
graphic and clinicopathological parameters of these samples is
shown in Table 1(B).
Approval for research on human subjects was obtained from
The Johns Hopkins University institutional review boards. This
study qualified for exemption under the U.S. Department of
Health and Human Services policy for protection of human
subjects [45 CFR 46.101(b)]. IRB guidelines were followed at each
of the involved institutions. All human materials used in the study
from the Department of Obstetrics and Gynecology, University
Campus Bio-Medico of Rome, Italy, were collected according to
the guidelines of the Local Ethical Committee of Campus Bio-
Medico of Rome. The guidelines of the Local Ethics Committee,
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Table 1. Demographic and clinicopathological data of Ovarian Cancer samples (Training set and independent validation set) and
Normal Ovarian samples.






Median 57 56 57 46
Range 23–79 37–77 23–77 40–55
Follow-up (months)
Median 24 37 30.5
Range 0–228 13–79 0–228
Race
Caucasian 24 24 48 0
African-american 8 0 8 0
Hispanic 0 0 0 13
Unknown 1 0 1 0
Tumor type
EOC* 33 18 51
Germ cell tumor 0 1 1
Metastasis 0 4 4
Unknown 0 1 1
Histology
Serous-papillary 33 11 44
Endometrioid 0 4 4
Mucinous 0 2 2
Undifferentiated 0 1 1
Unknown 0 6 6
Stage
I 15 6 21
II 1 4 5
III 14 12 26
IV 3 1 4
Unknown 0 1 1
Grade
Borderline 12 0 12
G1 0 2 2
G2 8 5 13
G3 13 12 25
GX** 0 1 1
Unknown 0 4 4
Chemotherapy
Yes 11 23 34
No 9 0 9
Unknown 13 1 14
Type of chemotherapy
Platinum/taxol after surgery 0 18 18
Platinum/taxol before and after surgery 0 6 6
Unknown 33 0 33
Recurrence
Yes 4 14 18
No 0 10 10
Unknown 29 0 29
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Table 1. Cont.






Yes 1 0 1
No 32 0 32
Unknown 0 24 24
Smoking
Smoker 2 5 7
Non-smoker 16 19 35
Unknown 15 0 15
Alcohol
Current 6 2 8
No 12 22 34
Unknown 15 0 15
B. Validation set




























Residual disease after surgery
,2 cm 184 49%
.2 cm 160 43%
Unknown 28 8%
Chemotherapy
No chemotherapy 56 15%
Platinum-containing 173 47%
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which are in default compliant to the Italian Protection Data
Authority, determines that samples collected retrospectively from
the Department of Pathology (formalin-fixed, paraffin-embedded
tissue) don’t need to have any approval and are exempted from
obtaining written informed consent. According to the Italian
Protection Data Authority rules (http://www.garanteprivacy.it/
web/guest/home_en doc web n 1884019), Italian Institutions are
in default authorized to use the samples and the corresponding
clinical data included in the study. All samples collected from
Hospital San Jose Tec de Monterrey, Monterrey, Mexico were
collected following the Ethical Committee rules. According to the
guidelines from the Mexican law for Health Research (Regla-
mento de la Ley General de Salud en Materia de Investigacio´n
para la Salud, article 23rd, 2nd title, 1st chapter: retrospective
studies are considered as non-risk studies and therefore do not
require a written informed consent of the participants or Ethical
Committee approval. Samples from Mexico were from archived
samples (formalin-fixed, paraffin-embedded tissue) and were
retrieved from the hospitals’ pathology archive. For the patients
obtained from the UMCG in The Netherlands, patients gave
informed consent for collection and storage of tissue samples in a
tissue bank for future research. All relevant patient data were
retrieved and transferred into an anonymous, password-protected,
database. The patients’ identity was protected by study-specific,
unique patient codes and their true identity was only known to two
dedicated data managers. According to Dutch regulations, these
precautions meant no further institutional review board approval
was needed (http://www.federa.org/). All patients’ data were de-
identified for the researchers in all 4 institutions.
Gene Selection
In the present study, we selected a total of 13 genes to analyze
their methylation status (using QMSP) by a candidate gene
approach. Genes were selected based on their cancer specific
methylation in OC and/or any other solid cancer types. The genes
selected were: PGP9.5, HIC1, AIM1, APC, PAK3, MGMT, KIF1A,
CCNA1, ESR1, SSBP2, GSTP1, VGF and FKBP4. A detailed
summary of information about these genes is available in
Table S1 in File S1.
Based on the alterations of above mentioned genes in cancer
(further discussed in the discussion section), we analyzed all these
13 genes in a training set of samples and selected two genes (VGF
and PGP9.5) for further analysis of a large well annotated
independent set of samples. The selection criteria of the genes to
be tested in the independent validation set were: a) Methylation
frequency in tumor samples in the training set; b) Methylation
frequency in normal samples; C) Novelty of the gene for OC; D)
Known functions of each gene by literature/PubMed search.
DNA extraction
After initial patient de-identification, all original OC histologic
slides were reviewed to reconfirm the diagnosis by a senior
pathologist. A representative block was retrieved for DNA
extraction. Histologic slides from the formalin-fixed, paraffin-
embedded tissue were taken. Slides were microdissected to obtain
.70% neoplastic cells. The microdissected normal ovarian
epithelium was isolated from ovarian tissue resected during
surgery, confirming afterwards the absence of any malignant
and/or pre-malignant process in the tissue. DNA was extracted
using the phenol-choloroform extraction protocol followed by
ethanol precipitation, as described previously [15]. For the
UMCG specimens, DNA was isolated using standard salt-
chloroform extraction and isopropanol precipitation. Precipitated
DNA was resuspended in Tris-EDTA buffer (10 mM Tris; 1 mM
EDTA, pH 8.0). Genomic DNA was amplified in a multiplex PCR
according to the BIOMED-2 protocol, to check the DNA quality
[16].
Sodium Bisulfite Treatment
DNA extracted from primary tumors and normal ovarian
epithelium was subjected to sodium bisulfite treatment, which
converts unmethylated cytosine residues to uracil residues, as
described previously [17]. For this, the EpiTect Bisulfite kit (Cat
No. 59104, QIAGEN Inc., Valencia, CA) was used as per the
Table 1. Cont.


















Unknown (n = 15)
*Epithelial ovarian cancer ** Grade cannot be assessed.
doi:10.1371/journal.pone.0070878.t001
VGF and PGP9.5 Methylation in Ovarian Cancer

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































VGF and PGP9.5 Methylation in Ovarian Cancer




















































































































































































































































































































































































































































































































































































































































































































































VGF and PGP9.5 Methylation in Ovarian Cancer
PLOS ONE | www.plosone.org 7 September 2013 | Volume 8 | Issue 9 | e70878
manufacturer instructions. For the UMCG samples, bisulfite
treatment was performed with the EZ DNA methylation kit
according to manufacturer’s protocol (Zymogen, BaseClear,
Leiden, the Netherlands). After treatment, DNA was stored at
280uC until used.
Methylation Analysis
Bisulfite-treated DNA was used as a template for fluorescence-
based real-time PCR, as previously described [17]. Amplification
reactions were carried out in triplicate in a final volume of 20 mL
that contained 3 mL of bisulfite-modified DNA; 600 nM concen-
trations of forward and reverse primers; 200 nM probe; 0.6 U of
platinum Taq polymerase (Invitrogen, Frederick, MD); 200 mM
concentrations each of dATP, dCTP, dGTP and dTTP; and
6.7 mM MgCl2. Primers and probes were designed to specifically
amplify the promoters of the 13 genes of interest and the promoter
of a reference gene, ACTB; primer and probe sequences and
annealing temperatures are provided in Table S2 in File S1.
Amplifications were carried out using the following profile: 95uC
for 3 minutes, followed by 50 cycles at 95uC for 15 seconds and
60uC for 1 minute. Amplification reactions were carried out in
384-well plates in a 7900HT sequence detector (Perkin-Elmer
Applied Biosystems, Beverly, MA) and were analyzed by a
sequence detector system (SDS 2.4; Applied Biosystems). Each
plate included patient DNA samples, positive (in vitro methylated
leukocyte DNA) and negative (normal leukocyte DNA or DNA
from a known unmethylated cell line) controls, and multiple water
blanks. Leukocyte DNA from a healthy individual was methylated
in vitro with excess SssI methyltransferase (New England Biolabs
Inc., Beverly, MA) to generate completely methylated DNA, and
serial dilutions (90–0.009 ng) of this DNA were used to construct a
calibration curve for each plate. All samples were within the
assay’s range of sensitivity and reproducibility based on amplifi-
cation of internal reference standard (threshold cycle [CT] value
for ACTB of 40). The relative level of methylated DNA for each
gene in each sample was determined as a ratio of methylation
specific PCR-amplified gene to ACTB (reference gene) and then
multiplied by 1000 for easier tabulation (average value of
triplicates of gene of interest divided by the [average value of
triplicates of ACTB] 61000). The samples were categorized as
unmethylated or methylated based on the sensitivity of the assay.
For VGF, bisulfite sequence analysis was also performed to
confirm the methylation status in the cell lines derived from
ovarian cancer (IGROV, IGROV CP, A2780, A2780 CP, 2008
Figure 1. Representative scatter plots showing methylation levels of PGP9.5 and VGF in ovarian tumor separated by samples’
clincopathological characteristics. Calculation of the PGP9.5 or VGF gene to b-actin ratios was based on the fluorescence emission intensity
values for both the genes obtained by quantitative methylation-specific real-time PCR analysis. The obtained ratios were multiplied by 1,000 for
easier tabulation. Zero values are indicated in the lower part of the graph, showing the amount of samples, as they cannot be plotted correctly on a
log scale. (A) PGP9.5 methylation values in normal samples (0/13, 0%), cystadenomas (12/17, 71%), borderline tumors (18/18, 100%) and ovarian
tumors (316/372, 85%). (B) Methylation of PGP9.5 throughout the histological types (O.R = 0.24, 95%C.I. [0.14–0.40], p,0.001). (C) PGP9.5 methylation
was significantly correlated with lower grade (O.R = 0.24, 95% C.I. [0.14–0.40], p= 0.012). (D) PGP9.5 methylation was significantly correlated with
absence of residual disease (lower than 2cm) (O.R = 0.41, 95%C.I. [0.24–0.68], p= 0.001). (E) PGP9.5 methylation was significantly correlated with early
stage of tumors (O.R = 0.26, 95%C.I.[0.16–0.45] p,0.001. (E) VGF methylation values and frequencies in normal samples (0/13, 0%), cystadenomas (5/
16, 31%), borderline tumors (6/18, 33%) and ovarian tumors (158/366, 43%).
doi:10.1371/journal.pone.0070878.g001
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and 2008 C13) and from normal ovarian surface epithelium (OSE)
cell lines (OSE2A, OSE2B and OSE7). Bisulfite treated DNA was
amplified for the 59 region that included at least a portion of the
CpG island within 1 kb of the proposed transcription start site
(TSS), contemplating the same area as the QMSP primers and
probe. The primers were designed not to contain CpG sites, and
considering the bisulfite treated sequence, in order to amplify the
region regardless of its methylation status, allowing us to observe it
without a reaction bias. The primers sequence were: Forward 59-
TTTGTTTTTGTTAGGGGGTTGTT-39 and Reverse 59- AA-
CACCAATAAAAACTAATACTA-39. PCR products were gel
purified using the QIAquick Gel Extraction kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. Each amplified
DNA sample was sequenced by the Applied Biosystems 3700
DNA analyzer using forward or reverse primers and BD
terminator dye (Applied Biosystems, Foster City, CA). Three
independent reactions were run to confirm the observed data.
Statistical Analysis
Statistical analysis was performed with IBM SPSS Statistics 19.0
(SPSS Inc., Chicago, IL). For each gene a methylation threshold
(cut-off) above the highest value in the control group was used to
achieve 100% specificity in the training set and the same cut-off
values were applied for VGF and PGP9.5 in independent validation
set, analysis were also performed using a cutoff in the 75th
percentile of methylation values. Differences in methylation
proportion between normals and cancers were assessed by Fisher’s
exact test. Furthermore, hypermethylation values for each gene
were also compared between cancer and normal by Mann-
Whitney U test. Correlations of the methylation levels of genes
were assessed with Spearman correlation coefficients. The
association between hypermethylation and the clinico-pathological
characteristics was assessed by logistic regression, chi-square and
Fisher’s exact tests, as appropriate. Overall survival (OS) was
defined as the time from diagnosis to death of any cause or last
follow-up visit alive. Disease-specific survival (DSS) was defined as
the period from diagnosis to death as a consequence of OC.
Differences in OS and DSS according to clinicopathological
characteristics and methylation of genes were analyzed using Cox
regression analysis. All significant variables with a P value ,0.05 in
univariate analysis were included in multivariate analysis. P values
of ,0.05 were considered statistically significant. All the P values
are two-sided.
5-aza-29-deoxycytidine treatment of cells and Reverse
transcription-PCR and real-time reverse transcription-
PCR.
We seeded (density: 16106) six ovarian cancer cell lines
(IGROV, IGROV CP, A2780, A2780 CP, 2008 and 2008 C13)
lines in their respective culture medium and maintained them for
24 h before treating them with 5 mM 5-aza-29-deoxycytidine (5-
aza-dC; Sigma) for 5 to 7 days. We renewed medium containing
5-aza-dC every 24 h during the treatment. We handled the
control cells (mock treated) in the same way, without adding 5-aza-
dC. We also treated 5-aza-dC in combination with trichostatin A
(TSA, Sigma, St. Louis, MO), a histone deacecetylase inhibitor,
and TSA alone. Stock solutions of 5-aza-dC were dissolved in
phosphate buffer saline PBS (pH 7.5). We prepared total RNA
using Qiazol (Qiagen Inc. Valencia, CA), following manufacturer’s
instructions.
Reverse transcription-PCR (RT-PCR)
cDNA was synthetized using Superscript III (Invitrogen, Life
Technologies, Carlsbad, CA), with an initial amount of 1ug of
RNA, following its standard protocol. RT-PCR was performed as
described previously [18]. One microliter of each cDNA was used
for real-time RT-PCR using specific primers and taqman probe
for the gene of interest. Amplifications were carried out in 384-well
plates in a 7900HT Sequence Detector System (Applied Biosys-
tems, Foster City, CA). Expression of genes relative to glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) was calculated
based on the threshold cycle (Ct) as 22D(DCt), where DCt =
Ct,GENE2Ct,GAPDH and D (DCt) = DCt,AZA2DCt,M (M, mock
treatment; Aza, 5-aza-dC treatment) [19].
Colony focus assay
We compared the methylation profile and expression of VGF in
3 normal ovarian surface epithelium (OSE) cell lines (OSE2A,
OSE2B and OSE7) and 3 pairs of isogenic OC cell lines (A2780
and A2780CP, 2008 and 2008C13, and IGROV and IGROV
CP) different in regards to cisplatin sensitivity. We then performed
focus formation assay for VGF using two cell lines (2008 and
2008C13) that were methylated and not expressing VGF.
Table 4. Cox proportional hazards model of variables
predicting decreased overall survival
UNIVARIATE ANALYSIS
Variables
P value HR 95% C.I.
Age (.61) 0.001 1.57 1.19 2.06
Histology (serous) ,0.001 2.46 1.74 3.48
Grade (III/undifferentiated) ,0.001 1.91 1.42 2.56
Stage (III/IV) ,0.001 8.22 4.91 13.76
Residual disease after surgery (.2 cm) ,0.001 4.73 3.47 6.44
PGP9.5 methylated 0.004 0.59 0.42 0.84
VGF methylated 0.028 0.73 0.55 0.97
MULTIVARIATE ANALYSIS
Covariate
PGP9.5 methylated 0.524 1.15 0.74 1.80
Age (continuous) 0.378 1.01 0.99 1.02
Histology (serous) 0.671 1.10 0.70 1.73
Grade (III/undifferentiated) 0.769 1.05 0.75 1.48
Stage (III/IV) ,0.001 4.56 2.26 9.22
Residual disease after surgery (.2 cm) ,0.001 2.70 1.84 3.97
Covariate
VGF methylated 0.005 0.62 0.44 0.87
Age (continuous) 0.215 1.01 1.00 1.02
Histology (serous) 0.509 1.16 0.74 1.81
Grade (III/undifferentiated) 0.529 1.12 0.79 1.58
Stage (III/IV) ,0.001 4.04 2.02 8.11
Residual disease after surgery (.2 cm) ,0.001 2.76 1.88 4.04
Covariate
VGF methylated 0.014 0.69 0.51 0.93
Stage (III/IV) ,0.001 4.67 2.67 8.16
Residual disease after surgery (.2 cm) ,0.001 2.79 2.00 3.88
BOLD P#.05 was considered statistically significant.
doi:10.1371/journal.pone.0070878.t004
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OC cell lines 2008 and 2008C13 were seeded in 10 cm dishes
and transfected with VGF expression vector (pCMV6-AC-VGF-
GFP) and empty vector (pCMV6-AC-GFP) (Origene, Rockville,
MD). Twenty-four hours after transfection, cells were split into
several dishes. From the following day, cells were cultured for
2 weeks in medium containing 400 mg/mL and 30 mg/mL of
G418 (Cellgro, Manassas, VA) for 2008 and 2008C13 respectively.
After 2 weeks cells were washed twice with PBS, fixed with 25%
acetic acid and 75% methanol at room temperature for
10 minutes and then stained with 0.1% crystal violet. Colonies
were counted and the number of colonies per dish was averaged
from three independent experiments (colonies.2 mm in diameter
were considered as positive). To confirm the expression of VGF,
cells were harvested 48 hours after transfection and western blot
analysis was performed, utilizing VGF antibody (Santa Cruz, CA),
normalized by b-actin levels (antibody from Sigma-Aldrich, Saint
Louis, MO).
Results
Overall methylation frequency on OC Samples and
Normal Ovarian Samples (Training Set)
Thirteen genes (PGP9.5, HIC1, AIM1, APC, PAK3, KIF1A,
CCNA1, ESR1, SSBP2, GSTP1, MGMT, VGF and FKBP4) were
analyzed for PH using QMSP in two different set of samples. The
observed methylation frequencies of each gene for the training set
are summarized in Table 2A. Briefly, in the training set (total), the
most frequently methylated genes were: PGP9.5, HIC1, ESR1 and
VGF. The observed frequency of methylation in this set was 19%
(11/57) for ESR1, 67% (38/57) for HIC1, 28% (16/57) for PGP9.5
and 37% (21/57) for VGF. Each of the latter 4 genes were
significantly more methylated in OC than normal (p =,0.05 for
each gene). Combining all 4 genes analyzed in the training set, we
observe methylation in at least 1 of the 4 genes in 81% (46/57) of
the OC samples, with a specificity of 100%.
This set of tumor samples were analyzed for gene pre-selection
purpose only. To maximize specificity, an empiric cut-off value
Figure 2. Kaplan-Meier curves for the studied populations stratified by gene methylation status and also stage. (A) Kaplan-Meier
curve for the study population stratified for PGP9.5 methylation. Overall survival was significantly higher in patients with PGP9.5 methylation. By Cox
regression univariate, the hazard ratio [HR] is 0.59, 95% CI [0.42–0.84], p= 0.004. (B) Kaplan-Meier curve for the study population stratified for PGP9.5
methylation and stage. Patients with early stage (stages I and II) showed better survival than those with late stage (stages III and IV) (P,0.001). Both
groups had similar survival when methylated PGP9.5 was compared to unmethylated (p= 0.524). (C) Kaplan-Meier curve for the study population
stratified for VGFmethylation. Overall survival was significantly higher in patients with VGFmethylation. By Cox regression univariate, the hazard ratio
[HR] is 0.73 [95%CI; 0.55–0.97], p= 0.028. (D) Kaplan-Meier curve for the study population stratified for VGF methylation and stage. Patients with early
stage (stages I and II) showed better disease specific survival than those with late stage (stages III and IV) (p,0.001). Both groups had a trend for
better survival when VGF was methylated compared to unmethylated.
doi:10.1371/journal.pone.0070878.g002
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was determined above the highest value in the control group for
each gene. The cut-off value of each gene is shown in Table 2A.
Association between DNA methylation changes and
clinicopathological factors in the training set
We compared the methylation status of two genes (PGP9.5 and
VGF) in 57 OC samples of the training set to demographic and
clinicopathological parameters such as age, stage, histological type,
grade, smoking and alcohol consumption history of the patients,
by logistic regression analysis. VGF methylation was more
frequently present in earlier stages (Stage I and II) of OC in
comparison with late stage (Stage III and IV) of tumors [14/26
(54%) versus 6/30 (20%) methylated] (Odds ratio, O.R=0.21,
95C.I. [0.07–0.7], p value = 0.011). Correlations with all other
Figure 3. Analysis of VGF methylation and expression. (A) Three representative sequences (electropherograms) of promoter sequencing of
VGF after Sodium bisulfite DNA conversion in OC cell lines. Upper panel shows IGROV with the respective unmethylated CG dinucleotides (we can
observe the indicated TGs by a circle) and lower panel shows 2008 and 2008C13 with the respective CG dinucleotides methylated. All cytosines
present after sodium bisulfite sequencing are corresponding to methyl cytosines. The thimidines represent the absence of methylation on the
cytosines on that same spot. (B) Bar graph showing expression and methylation data side by side. Light grey bars represent methylation assessed by
Quantitative Methylation Specific PCR (QMSP) in 6 tumor cell lines and 3 normal ovarian epithelium cells, Dark grey bars mRNA expression level by
RT-PCR on the same cell lines. (C) 2008 ovarian cancer cell line treated with the demethylating agent 5-aza-29-deoxycytidine (5-aza-dC) alone and in
combination with the histone deacethylase inhibitor Trichostatin (TSA), or with TSA alone, and mock treated for all mentioned conditions. Re-
expression of VGF was determined after 5 days, 7 days of treatment, treatment with TSA alone or the combination of both drugs. AZA, 5-aza-dC; NTC,
non template control (water). (D) Bar graph showing expression and methylation data side by side. Light grey bars represent methylation assessed by
QMSP in 4 tumors, Dark grey bars mRNA expression level by RT-PCR on the same tumors. (E) Ectopic expression of VGF inhibits tumor cell growth.
Upper panel: The effect of ectopic VGF-expression on ovarian carcinoma cell clonogenicity was investigated by monolayer colony formation assay.
Cells were transfected with VGF overexpression vector (pCMV6-AC–VGF–GFP) or control vector (pCMV6-AC-GFP), and selected with G418 on the
ovarian cancer cell line 2008 C13. Lower panel, Bar graph showing the number of colonies observed (larger than 2mm). No colonies were observed
after over expressing VGF containing vector while numerous colonies were observed after control vector transfection.
doi:10.1371/journal.pone.0070878.g003
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clinicopathologic parameters were not significant with methylation
of any of the other genes (Table 3A).
Methylation frequency of VGF and PGP9.5 in the
independent validation (IV) set of samples and
clinicopathological correlation
Based on the availability of samples and novelty of genes for OC
and methylation frequencies in the training set, we selected 2 genes
(VGF and PGP9.5) to test in an independent cohort of samples
consisting of 372 carcinomas, 18 borderline tumors and 17
cystadenomas. Both VGF and PGP9.5 methylation showed a
cancer specific pattern, with 43% and 85% frequency respectively
in tumors, while 0% in normals, as stated previously (Table 2B)
(Figure 1). Interestingly high methylation frequency was observed
for both genes in borderline tumors and cystadenoma (Table 2B)
(Figure 1).
In the independent validation set, using univariate logistic
regression analysis, we compared the methylation status of VGF
and PGP9.5 to demographic and clinicopathological parameters
such as age, stage, histological type, grade, and presence of
residual disease after surgery. PGP9.5 methylation (using the
cutoff above the 75th percentile of methylation ratio) was
significantly correlated with lower grade and early stage of
tumors (O.R= 0.52, 95% C.I. [0.31–0.86], p=0.012) and
(O.R= 0.27, 95% C.I.[0.16–0.45], p,0.001), respectively, as
well as with absence of residual disease (O.R= 0.41,
95%C.I.[0.24–0.68], p=0.001) and histological type (non-serous)
(O.R= 0.24, 95%C.I.[0.14–0.40], p,0.001) (Table 3B)
(Figure 1). A summary of methylation of VGF and PGP9.5 with
clinicopathological correlation in independent validation set are
shown in Table 3B.
All the 372 cases of ovarian carcinoma of the independent
validation set were available for follow up analysis. We used Cox
Proportional Hazard Model to predict overall survival (OS) and
disease specific survival (DSS) of these 372 patients associated
with PH of PGP9.5 and VGF. Median follow up for these patients
were 30 months, ranging from 1 to 234 months. Consistent with
previous observation, by a univariate cox regression analysis, we
found correlation of poor survival with later stage (III/IV) of
tumor (Hazard Ratio (HR) 8.22, 95% C.I [4.91–13.76],
p,0.001), and presence of residual disease (HR 4.73, 95%CI
[3.47–6.44], p,0.001) (Table 4). Methylation status of each of
the genes was a critical factor for predicting patient OS and DSS.
In univariate cox regression analysis, presence of PGP9.5
methylation correlated significantly with better patient overall
survival (HR 0.59, 95%CI [0.42–0.84], p = 0.004) and DSS (HR
0.57, 95%CI [0.39–0.82], p = 0.003). Figure 2A shows the
Kaplan-Meier curve for OS depending on the methylation status
of PGP9.5. However, these findings did not remain significant in
the multivariate analysis (Table 4), we can observe a Kaplan-
Meier curve for OS separated by stage depending on the
methylation status of PGP9.5 (Figure 2B). Similarly univariate
cox regression and Kaplan Meier analysis (Table 4) were
performed for VGF. OS was significantly higher in patients with
VGF methylation (HR 0.73, 95% CI [0.55–0.97], p = 0.028)
(Figure 2C), as well as DSS (HR 0.72, 95%CI [0.54–0.96],
p = 0.027). After adjusting for tumor stage and presence of
residual disease, in a multivariate model, VGF methylation
remained as a good predictor of better survival: OS (HR 0.61,
95%CI [0.43–0.86], p,0.005) (Table 4) and DSS (HR 0.58,
95%CI [0.41–0.83], p,0.003). Figure 2D shows a Kaplan-
Meier curve for DSS separated by stage depending on the
methylation status of VGF.
VGF promoter methylation correlates with expression in
cell lines and primary tumors; and overexpression of VGF
inhibits OC cell growth in vitro
We tested OC derived cell lines (A2780 and A2780CP, 2008
and 2008C13, and IGROV and IGROV CP) as well as normal
ovarian epithelium cell lines (OSE2A, OSE2B and OSE7) for VGF
methylation. Figure 3A shows the representative bisulfite
sequencing chromatogram for 2008, 2008C13 and IGROV OC
cell lines. We further tested the methylation status of VGF for all
the latter cell lines by QMSP. Figure 3B shows normalized
methylation values of these cell lines. As evident in the Figure 3
ovarian normal and 4 OC cell lines do not have any promoter
methylation for VGF while 2 ovarian cell lines (2008 and 2008C13)
demonstrated PH (Figure 3B). To determine whether promoter
methylation of VGF has any effect on its expression, we assessed
mRNA expression level of VGF by Quantitative RT-PCR of the
same cell lines and indeed observe that promoter methylation
inversely correlated with VGF expression in all cell lines
(Figure 3B). No expression of VGF in 2008 and 2008C13 OC
cell lines were observed with promoter methylation. To further
confirm methylation indeed related to expression, we treated the
2008 OC cell line with the demethylating agent 5-aza-29-
deoxycytidine (5-aza-dC) alone and in combination with the
histone deacethylase inhibitor Trichostatin (TSA), or with TSA
alone, and mock treated for all mentioned conditions. Re-
expression of VGF was determined after 5 and more noticeable
7 days of treatment, treatment with TSA alone or the combination
of both drugs (Figure 3C). Notably, synergistic treatment of 5-
aza-dC and TSA induced robust expression of VGF.
To determine the correlation of VGF PH with gene expression
in in vivo situations, we assessed the methylation status of VGF and
mRNA level expression in 4 OC patients (matched samples). We
observed expression of VGF generally correlated with promoter
methylation (Figure 3D). The lack of direct relationship between
the presence of methylation and total absence of expression can be
due to the fact that our samples still retain normal cells that could
be responsible for this low level expression. Another possible
reason could be the level of methylation observed may not be
enough to completely shut down VGF expression.
To determine the biologic consequences of VGF, we forcefully
introduced VGF into two OC cell lines (2008 and 2008C13) and
performed focus formation assays. VGF expression vector (pCMV6-
AC–VGF–GFP, OriGene Technologies, Inc., Rockville, MD), as
well as the empty vector (pCMV6-AC-GFP, OriGene Technologies,
Inc.) were transfected into 2008 and 2008C13 OC cell lines that
have fully methylated and silenced VGF. The colony focus formed
by VGF-transfected cells were significantly less and smaller in size
than those of empty vector transfected cells. Representative data
are shown in Figure 3E.
Discussion
Our main goal in this study was to define a set of methylation
markers capable of distinguishing ovarian carcinoma and normal
ovarian tissue, and also to identify a panel of biomarkers that are
correlated with patient’s clinicopathological characteristics.
We selected the initial 13 genes to be analyzed based on
previous reports in the literature. Aberrant methylation of GSTP1
and MGMT were exclusively demonstrated in invasive ovarian
carcinomas [20], differentiating between ovarian tumors with low
malignant potential and invasive ovarian tumors. GSTP1 and
MGMT, (involved in DNA repair/drug detoxification) methylation
have also been associated with a higher response to chemotherapy
in OC [21]. The role of ESR1 in OC remains unclear; some
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investigators have found hypermethylation in malignant ovarian
tumors and low malignant potential ovarian tumors [22]. KIF1A is
an anterograde motor protein that transports membranous
organelles along axonal microtubules. As a part of ‘‘Cancer
Methylome’’ discovery, we tested a small number of OC samples
and found a high frequency of PH of KIF1A in OC [17]. Cancer-
specific methylation of activated kinase 3 (PAK3) was found in
several neoplasms, including OC with high frequency [17]. HIC1
is a potential TSG and found to be methylated in several solid
tumors including OC [23–25]. In the study by Tokumaru et al.
[26] PGP9.5 was found to have a high frequency of PH in a large
panel of primary tumors, and their data support the notion that
this gene is a TSG that is inactivated by PH or gene deletion in
several types of human cancers. Some genes were described as
hypermethylated in other cancer types, these include SSBP2, [27],
CCNA1 [28,29], AIM1 [30], VGF [17], FKBP4 [31], and we
decided to evaluate their promoter methylation status in ovarian
tissues samples.
From the initial 13 genes analyzed in the training set, two genes
were further explored in an independent set of samples. ESR1,
PGP9.5, HIC1 and VGF showed cancer specific methylation
pattern in the training set explored, and we chose PGP9.5 and VGF
to be further explored in an independent validation set. Multiple
groups had previously shown HIC1 to be frequently methylated in
OC samples [23–25] and our findings could corroborate these
data, although the reported frequencies vary from 17 to 50%, all
using less sensitive techniques than ours that showed a frequency
of 65%. ESR1 has been found hypermethylated in malignant
ovarian tumors and low malignant potential ovarian tumors [22],
but was the least frequent in our training set (Table 2). So due to
lack of novelty and sample availability, we did not included HIC1
and ESR1 in the validation set.
PGP9.5, also known as UCHL1, is a neuro-specific peptide that
removes ubiquitin from ubiquinated proteins and prevents them
from targeted degradation by proteasomes [32]. Our group and
others showed PGP9.5 inactivation by PH in several types of solid
tumors [28,33,34]. Mizukami et al. observed a frequent methyl-
ation pattern of PGP9.5 in colorectal cancer where it was more
frequently methylated in patients with earlier stages of colorectal
cancer than in metastatic cases [35]. We are reporting for the first
time that PGP9.5 is significantly more methylated in early stage
and lower grade of OC. There is controversy regarding the role of
PGP9.5 as a TSG or oncogene in cancer. In the study by
Tokumaru et al. PGP9.5 was found to have a high frequency of
PH in a large panel of primary tumors, and their data support the
notion that this gene is a TSG that is inactivated by PH [26]. On
the other hand, there are numerous reports that PGP9.5 is over-
expressed in a subset of primary cancers [26,36]. Over-expression
in primary cancer tissues could be the cause of or the result of
transformation. If it is the cause of transformation, PGP9.5 would
be an oncogenic molecule, but the clinical profile reported here
does not support this notion for OC as we observed significantly
more PGP9.5 methylation in early stage OC and no methylation
was determined in normal ovarian epithelium. In OC, PGP9.5 has
been analyzed before by conventional MSP and bisulfite
sequencing, and demonstrated a very low frequency in the 17
tumors analyzed (6%) [37]. The primers used in that study are
different from the primers we used in this study. In addition
Quantitative MSP is thought to be at least ten times more sensitive
than the conventional MSP they used in their study. Addition of
probe within the PCR product in QMSP provides additional
specificity by QMSP assay than conventional MSP.
VGF is a secreted neuropeptide, recently reported to be
methylated in cancer in a ‘‘Cancer Methylome’’ discovery
approach by our group [17]. We found high methylation
frequency of VGF in OC. We recently reported cancer specific
methylation of VGF in two other hormone related cancers (breast
and testicular) [31,38]. To our knowledge, there are no further
reports linking VGF and cancer. It will be interesting to further
explore the biologic relevance of VGF for the development of
hormone related cancer. VGF has been shown to play an essential
role in body weight, basal metabolism and nutrition [39]. In our
study, PH of VGF correlated with loss of gene expression in cancer
cell lines and primary ovarian tumor, and re-expression of VGF
could be obtained by inhibiting DNA methylation with 5-aza-dC.
However 5-aza-dC may be non-specific and induce VGF
expression may be due to alterations of related signaling pathways
and demethylating other genes which regulate the expression of
VGF. While additional studies are necessary to accurately
understand the role of VGF gene silencing during the multistep
process of tumorigenesis, our results argue that VGF may be one of
the most frequent targets of unscheduled silencing induced by
aberrant PH in the genesis of OC. It is well established that DNA
methylation of the CpG island in the promoter region is causally
involved in gene silencing [17], therefore a tight correlation
between VGF CpG island hypermethylation in cancer cell lines
and loss of gene expression in these cells provides an explanation
for the loss or inactivation of VGF previously reported in different
pathological conditions [40]. Interestingly we found synergistic
effect of 5-aza-dC and TSA for the induction of VGF expression.
So studies on histone modifications on VGF may also be
interesting. VGF knockout mice are reported to be hyperactive
and hypermetabolic [41] and tumors are also known to be
hypermetabolic. Further studies could be extended in tumors to
analyze this relationship in in vitro and in vivo model systems. From
a clinical point of view, our findings suggested that 5-aza-dC
treatment is able to restore VGF expression in cancer cell lines and
that over-expression of exogenous VGF inhibit colony formation of
OC cells. So DNA hypermethylation of VGF may represent an
attractive target for intervention strategies. However, further
biological roles of VGF in tumorigenesis need to be elucidated.
From the outcome perspective, the correlation of presence of
PH of these two genes (VGF and PGP9.5) with better overall and
disease specific survival is a potential indication of its utility in
clinics. The presence of methylation seems to be contributing for
the occurrence of cancer but, in this case, conferring better
prognosis. Inconsistent activity in developing tumorigenesis were
reported for PGP9.5 [26]. There are very limited functional
studies that have been performed for VGF and, to our knowledge,
no functional studies has been reported for VGF in cancer.
Although it needs to be proved, hypothetically one can argue that
these genes may have diverse roles in cancer. An example to
support this argument is MGMT promoter methylation; while
promoter methylation of MGMT has been reported as frequent in
several cancer types, thus being correlated with cancer initiation
and/or progression; Glioma patients harboring methylation of
MGMT were found to be more responsive to alkylating agents
than those without this epigenetic alteration [42], demonstrating
its potential use in clinics. Our data showed significance in
univariate analysis but not in multivariate analysis for PGP9.5.
However, considering that methylation of PGP9.5 was positively
correlated with the presence of residual disease and early stage,
which are strong prognostic factors for OC in univariate disease, it
is understandable why PGP9.5 methylation does not represent an
independent survival predictor when used in conjunction with this
clinical parameters. Interestingly, we found that VGF methylation
is an independent factor for predicting better survival for OC. The
clinical usefulness of an independent prognostic factor is its ability
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to more accurately predict patient survival when used with other
known prognostic factors. Such a marker would be invaluable to
physicians and patients in selecting treatment options. Among the
known predictors for OC, higher stages and presence of residual
diseases after surgery are the two most critical poor survival
predictors with a HR of 8.22 and 4.73 respectively in our
independent validation set of samples. When we performed
multivariate analysis of VGF with these two factors, VGF
methylation was still significantly related to better overall survival.
To explore the utility of VGF methylation as a clinical tool for
predicting survival of OC patients at diagnosis, a higher sample
size with longer follow-up and well annotated clinical data is
needed. Although biological relevance data is not available for
methylation of PGP9.5 and VGF in OC, our findings of
methylation based good prognosis markers are supported by a
recent study that reported PH of potential TSG FBXW7/hCDC4-b
being related to favorable prognosis of primary breast cancer [43].
Several methylation studies have been reported previously in
OC, and some of cancer specific methylated genes were shown to
be correlated with stage, prognosis, survival and resistance to
therapy. For example, IGFBP-3 hypermethylation was associated
with disease progression and death in OC, particularly in patients
with early stage disease [44]. A set of markers found to be
correlated with early stage in serum or plasma samples of OC
patients was composed of RASSF1A, BRCA1, APC, CDKN2A and
DAPK [4]. From these, RASSF1A, has been shown in another study
to bind to tubulin and stabilize microtubules, thereby, assisting
paclitaxel in mediating the prevention of spindle assembly [45]. In
addition, silencing of hMLH1 has been linked with resistance to
platinum drugs as well [46]. Ozdemir et al. [47] analyzed 24 genes
by two different techniques that showed identical results and
observed CDKN2B as frequently methylated in OC and observed
that 40% of the samples analyzed had at least one of these genes
methylated. Other genes like SFRP1, SFRP2, SOX1, LMX1A,
TUSC3 and HOXA11 have been found to be correlated with
recurrence and overall survival/outcome of OC patients, being
HOXA11 independently associated with poor outcome [48–50].
Hypermethylation of TUSC3, a putative TSG, was associated with
significant shorter progression-free and overall survival rates in
OC, independently of other known risk factor [50]. Dai et al.
showed that NLD1 and DVL1 methylation are independently
associated with progression free survival, being potential markers
of good prognosis [51]. Zeller et al. [52] examined genome-wide
methylation in order to establish differences and similarities
among ovarian tumors classified as Low-grade serous carcinomas
(LGSC), serous borderline ovarian tumors (SBOT) and benign
serous tumors (BST), since few is known about the progression
from benign lesions of the ovary to serous carcinomas, as well as
what are the characteristics that allow the genesis of LGSC from
borderline tumors. They found that DNA methylation profiles
could separate between BST and LGSC, but not between LGSC
and SBOT. They could not identify a classifier for distinguishing
SBOT with benign or malignant like methylation profile, however
they could observe that LGSC and SBOT have different profiles
than benign lesions, being very similar among each other. All these
markers represent some examples of how epigenetic changes, like
DNA methylation, can drive genes to have a role in ovarian
carcinogenesis. More examples of markers with a role in OC can
be found in a more extensive and detailed review from our group
[53].
It has been long recognized that inactivation by DNA PH is one
of the hallmarks of cancer. We chose to use a candidate gene
approach, where genes known to be inactivated in several types of
cancer were examined in ovarian samples. In this work, we made
the option of examining independent cohorts of OC samples to
truly elucidate the PH frequency and importance of our selected
candidate genes. The present study not only contributes with an
analysis of a panel of methylation regulated genes in ovarian
carcinoma, revealing genes with cancer specific patterns, but also
highlights the enormous possibilities of identifying new molecular
markers that will allow the translation of this knowledge to the
daily clinics, permitting the accurate selection of patients to
different therapies based on their molecular profile.
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